AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10096580
Drug: anti-IFN-alpha vaccine
RxNorm normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-IFN-alpha vaccine
Trial: 31953844
Drug: Mindlessness meditation
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindlessness meditation (ML)
Trial: 30452125
Drug: TIVA (propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIVA (propofol and remifentanil infusion)
Trial: 30452125
Drug: DES (desflurane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DES (desflurane inhalation and remifentanil infusion)
Trial: 23262204
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of temsirolimus (25 mg IV weekly) and bevacizumab (10 mg/kg every other week)
Trial: 23262204
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of temsirolimus and bevacizumab
Trial: 19692044
Drug: Emollient cream
RxNorm normalized name: EMOLLIENT CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emollient cream (placebo group 1)
Trial: 19692044
Drug: Topical triamcinolone
RxNorm normalized name: triamcinolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical triamcinolone (nonblinded treatment for nonresponders)
Trial: 14763724
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (monthly education material and quarterly telephone calls)
Trial: 3019810
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day mebeverine
Trial: 28107891
Drug: Telephone-administered cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered cognitive behavioral stress management (T-CBSM), N=56
Trial: 28107891
Drug: Live cognitive
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live cognitive behavioral stress management (L-CBSM), N=44
Trial: 23184666
Drug: Anagrelide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anagrelide (1 mg) with food/caffeine (standardized breakfast including two cups of coffee)
Trial: 23184666
Drug: Anagrelide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anagrelide (1 mg) in a fasted state
Trial: 14528202
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (combination heat probe coagulation and injection therapy)
Trial: 8826542
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg d-amphetamine (AMP)
Trial: 15362251
Drug: Estrogen and
RxNorm normalized name: Conjugated estrogen and norgestrel only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen and progesterone therapy
Trial: 15362251
Drug: Thyroid therapy
RxNorm normalized name: THYROID THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid therapy
Trial: 9137847
Drug: Divalproex sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex sodium 500 mg
Trial: 9137847
Drug: Divalproex sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex sodium 1000 mg
Trial: 9137847
Drug: Divalproex sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex sodium 1500 mg
Trial: 3137036
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg pefloxacin b.i.d.
Trial: 3137036
Drug: 160/800 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160/800 mg cotrimoxazole b.i.d.
Trial: 18461609
Drug: Adefovir/lamivudine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adefovir/lamivudine combination therapy
Trial: 29443767
Drug: Oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone hydrochloride 0.5 mg/kg + flurbiprofen axetil 150 mg
Trial: 29443767
Drug: Oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone hydrochloride 0.75 mg/kg + flurbiprofen axetil 150 mg
Trial: 29443767
Drug: Oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone hydrochloride 1.0 mg/kg + flurbiprofen axetil 150 mg
Trial: 26714442
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 1 mcg/kg (Group L)
Trial: 26714442
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 2 mcg/kg (Group H)
Trial: 26714442
Drug: Second oral
RxNorm normalized name: 60 Second Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second oral dose chloral hydrate 25 mg/kg (Group C)
Trial: 18707985
Drug: High-bolus dose
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-bolus dose tirofiban (n=491)
Trial: 16372826
Drug: Prulifloxacin 600mg
RxNorm normalized name: Orbifloxacin
DrugBank: Prulifloxacin (DB11892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prulifloxacin 600mg administered orally
Trial: 11260412
Drug: Cyclosporine plus
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine plus low-dose prednisone
Trial: 3935120
Drug: Glibenclamide (2.5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (2.5-10 mg daily)
Trial: 3935120
Drug: Chlorpropamide (125-500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpropamide (125-500 mg daily)
Trial: 29590326
Drug: Zoster Vaccine
RxNorm normalized name: ZOSTER VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoster Vaccine Live (ZV)
Trial: 26110349
Drug: Beta-Alanine (BA)
RxNorm normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-Alanine (BA) supplementation (800 mg + 8 g dextrose)
Trial: 26110349
Drug: Placebo (PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA) (8 g dextrose)
Trial: 24650125
Drug: Multimodal analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analgesia (dexamethasone, gabapentin, ibuprofen, paracetamol)
Trial: 24650125
Drug: Traditional morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional morphine and paracetamol regimen
Trial: 22288671
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (dipyrone 600 mg, isometheptene 60 mg, caffeine 60 mg)
Trial: 15818745
Drug: Morphine associated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine associated with GTN
Trial: 15818745
Drug: Morphine associated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine associated with ISDN
Trial: 15818745
Drug: Morphine associated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine associated with PTN
Trial: 12421266
Drug: Schedule A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule A: one dose at 0, 1, and 6 months
Trial: 12421266
Drug: Schedule B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule B: one dose at 0, 10, and 21 days
Trial: 2593767
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) administered intravenously
Trial: 2593767
Drug: Saline administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline administered intravenously
Trial: 29695772
Drug: Self-monitoring device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-monitoring device for daily salt intake
Trial: 28545917
Drug: RYGB patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RYGB patients receiving oral antibiotics
Trial: 28545917
Drug: Controls receiving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controls receiving oral antibiotics
Trial: 24091318
Drug: Standard fortification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fortification (3 g/kg/d)
Trial: 24091318
Drug: Moderate fortification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate fortification (3.3 g/kg/d)
Trial: 24091318
Drug: Aggressive fortification
RxNorm normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive fortification (3.6 g/kg/d)
Trial: 18248158
Drug: Active laser
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active laser therapy (LLLT)
Trial: 11012498
Drug: Intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal fentanyl 25 microg and ropivacaine 2.5 mg
Trial: 11012498
Drug: Intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal fentanyl 25 microg and bupivacaine 2.5 mg
Trial: 8994314
Drug: Combined hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined hepatitis A and B vaccine (3 doses of 1 ml each, containing at least 720 ELISA Units of HAV antigen and 20 micrograms of recombinant HBsAg, administered at 0, 1, and 6 months)
Trial: 1427652
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with lymphoblastoid interferon-alpha and levamisole (150 mg three times per week)
Trial: 1427652
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with lymphoblastoid interferon-alpha and levamisole
Trial: 3880877
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 gel administered intracervically
Trial: 3880877
Drug: Demoxytocin buccal
RxNorm normalized name: demoxytocin
DrugBank: Demoxytocin (DB13798)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demoxytocin buccal tablets
Trial: 31135822
Drug: Accelerated approval
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated approval drugs pending confirmatory data
Trial: 31135822
Drug: Drugs with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs with regular approval
Trial: 25461793
Drug: Work-related cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Work-related cognitive-behavioral therapy (WCBT) plus vocational services as usual (VSAU)
Trial: 25461793
Drug: Work-related cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Work-related cognitive-behavioral therapy (WCBT)
Trial: 21034483
Drug: Integrative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative care pathway involving exercise, massage, acupuncture, and cognitive behavioral therapy.
Trial: 15803929
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide (IVCY)
Trial: 15803929
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose IVCY induction followed by AZA maintenance
Trial: 15803929
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose IVCY induction followed by AZA maintenance
Trial: 15803929
Drug: Short-term oral
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term oral CY induction followed by AZA maintenance
Trial: 12160098
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of alcohol (0.62 g/kg)
Trial: 667244
Drug: Chlordiazepoxide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlordiazepoxide (10 mg and 20 mg)
Trial: 667244
Drug: Caffeine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (150 mg and 300 mg)
Trial: 667244
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and 'no-drug' treatment
Trial: 18927148
Drug: Home oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home oxygen therapy with support from 'hospital in the home' (HiTH)
Trial: 14999696
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) at a dose of 13 to 15 mg/kg/d for 2 years
Trial: 9260729
Drug: Aptiganel hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aptiganel hydrochloride (CNS 1102) infused over 4 hours at doses of 15, 32, 50, or 73 microg/kg
Trial: 9260729
Drug: Aptiganel hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aptiganel hydrochloride (CNS 1102) at total doses of 32 microg/kg
Trial: 9260729
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of Aptiganel hydrochloride (CNS 1102)
Trial: 9260729
Drug: Aptiganel hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aptiganel hydrochloride (CNS 1102) at total doses of up to 32 microg/kg infused over 4 hours
Trial: 3481040
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HDMTX) 1000 mg/m2 iv over 24 hours weekly for 3 weeks, then every 6 weeks for 72 weeks, combined with low-dose 6-mercaptopurine (6MP; 50 mg/m2 orally per day) and methotrexate (MTX; 25 mg/m2 orally per week)
Trial: 24665163
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) 300mg orally once daily for 3 months
Trial: 12605586
Drug: Glutamine supplementation
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine supplementation (0.56 g x day(‐1) x kg(‐1))
Trial: 10952476
Drug: MS Contin
RxNorm normalized name: MS Contin
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MS Contin tablets (MSC)
Trial: 10952476
Drug: Controlled-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release morphine sulphate suppository (MSR)
Trial: 8975964
Drug: α-interferon treatment
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-interferon treatment
Trial: 1547765
Drug: Nifedipine (NFD)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (NFD) 20 mg b.i.d. for 4 weeks
Trial: 1547765
Drug: Nifedipine (NFD)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (NFD) 40 mg b.i.d. for 4 weeks
Trial: 3113957
Drug: Metoprolol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol plus intravenous nitroglycerin (Group 2)
Trial: 28933582
Drug: Systane® Ultra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systane® Ultra treatments
Trial: 24993741
Drug: Triple eradication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple eradication treatment for H. pylori
Trial: 16847013
Drug: Immediate antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate antibiotics (chloramphenicol eye drops; n = 104)
Trial: 16847013
Drug: Delayed antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed antibiotics (n = 109)
Trial: 16847013
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics (controls; n = 94)
Trial: 16847013
Drug: Immediate antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate antibiotics (n = 104)
Trial: 15193674
Drug: Verapamil 240
RxNorm normalized name: verapamil 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 240 mg twice daily for six months
Trial: 10960931
Drug: 5-FU and
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU and its modulation (specific agent, dose, and route not detailed)
Trial: 9316554
Drug: High-dose hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose hepatitis B vaccine (40 micrograms at 0, 1, 2, and 6 months)
Trial: 9316554
Drug: Standard-dose hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose hepatitis B vaccine (20 micrograms at 0.1, and 6 months)
Trial: 8403467
Drug: Topical n‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical n‐6 essential fatty acids (evening primrose oil) added to 0.1% betamethasone valerate
Trial: 8403467
Drug: 0.1% betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% betamethasone valerate twice daily for 3 weeks
Trial: 3744133
Drug: Intravenous unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous unfractionated heparin (UFH) 240 anti‐Xa U/kg/12 h
Trial: 3744133
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin Fragmin 240 anti‐Xa U/kg/12 h
Trial: 3744133
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin Fragmin 120 anti‐Xa U/kg/12 h
Trial: 3744133
Drug: Subcutaneous Fragmin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Fragmin 120 anti‐Xa U/kg 2 times daily
Trial: 26947719
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (up to 300 units), administered subcutaneously, two injections 12 weeks apart.
Trial: 26947719
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered subcutaneously, two injections 12 weeks apart.
Trial: 18507107
Drug: suspension-emulsion
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suspension-emulsion
Trial: 12816878
Drug: 4 egg
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 egg yolks daily
Trial: 12816878
Drug: 2 egg
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 egg yolks daily
Trial: 10360660
Drug: Paclitaxel 135
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 135 mg m(‐2) by 24‐h intravenous infusion + cisplatin
Trial: 10360660
Drug: Paclitaxel 250
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 250 mg m(‐2) by 24‐h intravenous infusion + cisplatin + granulocyte colony‐stimulating factor (G‐CSF)
Trial: 10360660
Drug: Paclitaxel 135
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 135 mg m(‐2) + cisplatin administered as an outpatient by 3‐h infusion
Trial: 7741793
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen (E2) substitution (4 mg)
Trial: 2126836
Drug: Erdosteine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdosteine (300 mg 3 times daily for 2 weeks)
Trial: 27064975
Drug: IM20 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM20 × 3 (3 intramuscular standard-dose injections of 20-μg at weeks 0, 4, and 24)
Trial: 27064975
Drug: IM40 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM40 × 4 (4 intramuscular double-dose injections of 40-μg at weeks 0, 4, 8, and 24)
Trial: 27064975
Drug: ID4 ×
RxNorm normalized name: Idarubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ID4 × 4 (4 intradermal low-dose injections of 4-μg at weeks 0, 4, 8, and 24)
Trial: 20584070
Drug: telmisartan at
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: telmisartan at 80 mg day(‐1)
Trial: 20584070
Drug: enalapril at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril at 10 mg day(‐1)
Trial: 12401533
Drug: Compliance with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compliance with Step II dietary goals (≤30% of total calories from fat, <7% of calories from saturated fat, daily dietary cholesterol <200 mg)
Trial: 12401533
Drug: Consumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consumption of five or more daily servings of fruits or vegetables
Trial: 10099039
Drug: 5.0 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg/d isradipine
Trial: 10099039
Drug: 7.5 mg/d
RxNorm normalized name: Arixtra 7.5 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg/d isradipine